following a full submission:
lipegfilgrastim (Lonquex®) is accepted for restricted use within NHS Scotland.
Indication under review: Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
SMC restriction: where a long-acting granulocyte-colony-stimulating factor is appropriate.
In a randomised, double-blind study, in adults with breast cancer given myelosuppressive chemotherapy associated with a high risk of febrile neutropenia, lipegfilgrastim was compared with another long-acting granulocyte colony-stimulating factor when used as primary prophylaxis against febrile neutropenia. The study found lipegfilgrastim was non-inferior to the comparator preparation in terms of the mean duration of severe neutropenia in the first chemotherapy cycle.
Download detailed advice144KB (PDF)
Medicine details
- Medicine name:
- lipegfilgrastim, 6mg, solution for injection (Lonquex®)
- SMC ID:
- 908/13
- Indication:
- Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
- Pharmaceutical company
- Teva UK Limited
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 April 2014